Table 2 Factors associated with lost to follow-up over time among ART patients, N = 5901
Characteristic | Unadjusted odds ratios | Adjusted odds ratios | ||||
|---|---|---|---|---|---|---|
OR (95% CI) | P value | Global p value | OR (95% CI) | P value | Global p value | |
Site status | ||||||
Control intervention | 0.70 (0.65–0.76) | < .001 | < .001 | 0.70 (0.65–0.77) | < .001 | < .001 |
Age group, years | ||||||
< 10 years | ||||||
10–19 years | 1.41 (1.13–1.77) | 0.003 | 0.127 | 1.2 (0.95–1.5) | 0.126 | 0.187 |
20–29 years | 0.88 (0.76–1.02) | 0.087 | 0.88 (0.75–1.04) | 0.129 | ||
30–39 years | 0.94 (0.82–1.08) | 0.393 | 0.94 (0.8–1.12) | 0.499 | ||
40–49 years | 1.14 (0.98–1.33) | 0.093 | 1.01 (0.85–1.21) | 0.872 | ||
50–59 years | 0.92 (0.77–1.1) | 0.376 | 0.9 (0.74–1.11) | 0.335 | ||
60 + years | 1.12 (0.86–1.46) | 0.4 | 1.11 (0.83–1.47) | 0.482 | ||
Sex | ||||||
Male | ||||||
Female | 1.01 (0.94–1.09) | 0.713 | 0.713 | 0.95 (0.87–1.03) | 0.193 | 0.193 |
Marital status | ||||||
Divorced/Separated | ||||||
Married | 1.55 (1.25–1.92) | < .001 | < .001 | 1.34 (1.11–1.61) | 0.002 | < .001 |
Single | 2.97 (2.37–3.72) | < .001 | 1.39 (1.13–1.72) | 0.002 | ||
Widow | 1.56 (1.25–1.94) | < .001 | 1.43 (1.17–1.74) | 0.001 | ||
CD4 category | ||||||
< 200 | ||||||
200–350 | 1.49 (1.36–1.65) | < .001 | 0.678 | |||
350–500 | 1.07 (0.82–1.39) | 0.633 | ||||
≥ 500 | 0.98 (0.75–1.28) | 0.853 | ||||
WHO stage | ||||||
WHO IV | ||||||
WHO I | 2.75 (2.13–3.55) | < .001 | < .001 | 1.24 (0.98–1.58) | 0.076 | 0.026 |
WHO II | 1.71 (1.33–2.2) | < .001 | 1.36 (1.08–1.72) | 0.01 | ||
WHO III | 1.35 (1.05–1.73) | 0.019 | 1.27 (1.01–1.6) | 0.044 | ||
First line regimen | ||||||
Other | ||||||
Efavirenz | 1.90 (1.09–3.32) | 0.024 | < .001 | 1.83 (1.04–3.21) | 0.036 | < .001 |
Nevirapine | 3.18 (1.84–5.51) | < .001 | 2.82 (1.62–4.91) | < .001 | ||